Charles Moore

Charles Moore from Robert W. Baird & Co., on behalf of Jack Allen, asked for additional details on the trial design, endpoints, and desired outcomes for the upcoming graft-versus-host disease (GVHD) program.

Answer

President and CEO Dr. Jennifer Buell explained that the GVHD trial is advancing towards a first-in-human study planned for next year, targeting high-risk patients undergoing hematopoietic stem cell transplantation. The primary goals are to improve engraftment success and mitigate the risk of GvHD. She mentioned the control arm would likely be physician's choice, primarily corticosteroids, and promised that more formal details on the trial design and leadership would be shared on the next earnings call.

Charles Moore, on for Brian Skorney, asked about the potential advantages of Crinetics' nonpeptide approach for its GLP-1 and GIP assets relative to other peptide-based therapies in the obesity space.

Answer

CEO R. Struthers highlighted that small molecules overcome the manufacturing and delivery limitations inherent to peptides. He explained that this allows for greater flexibility in tuning physicochemical properties to optimize pharmacologic activity and pharmacokinetics, ultimately enabling the creation of a superior clinical profile that can be produced at scale.